{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:12:58Z","timestamp":1780737178076,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim was to employ site-dependent absorption of mirabegron (<jats:bold>MB<\/jats:bold>) as a guide for fabrication of oral disintegrating controlled release tablet (ODCRT) which undergoes instantaneous <jats:bold>release<\/jats:bold> of loading fraction followed by delayed release of the rest of MB. The goal was to release <jats:bold>MB<\/jats:bold> in a manner consistent with the chronobiology of overactive bladder (OAB) syndrome. In situ rabbit intestinal permeability of <jats:bold>MB<\/jats:bold> was adopted to assess absorption sites. <jats:bold>MB<\/jats:bold> was subjected to dry co-grinding with citric acid to develop the fast-dissolving fraction in the mouth. Delayed release fraction was formulated by ethanol-assisted co-processing with increasing proportions of Eudragit polymer (S100) as pH responsive polymer. The developed dry mixtures underwent thermal (DSC) and physical (X-ray diffraction) characterization, in addition to in vitro release behavior. Optimized fast dissolving and delayed release formulations were mixed with tablet excipient before compression in ODCRT which was assessed for release profile using continuous pH variation. <jats:bold>MB<\/jats:bold> underwent preferential permeation through ileum and colon. Co-grinding with citric acid provided co-amorphous powder with fast dissolution. Co-amorphization of <jats:bold>MB<\/jats:bold> with Eudragit S100 (1:5) showed pH-dependent release to <jats:bold>release<\/jats:bold> most of the dose at pH 7.4. The developed ODCRT <jats:bold>released<\/jats:bold> 43.5% of <jats:bold>MB<\/jats:bold> in the buccal environment and retained <jats:bold>MB<\/jats:bold> at acidic pH to start <jats:bold>release<\/jats:bold> at pH 7.4. The study successfully fabricated ODCRT guided by site-dependent absorption. The ODCRT instantaneously <jats:bold>released<\/jats:bold> loading fraction to support the patient after administration with delayed fraction to sustain the effect.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1208\/s12249-024-02865-z","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:02:31Z","timestamp":1721786551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intestinal Absorption Site-Guided Development and Evaluation of Oral Disintegrating Controlled Release Tablets of Mirabegron"],"prefix":"10.1208","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7634-967X","authenticated-orcid":false,"given":"Mohammed I.","family":"Ghanem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-882X","authenticated-orcid":false,"given":"Shimaa M.","family":"Ashmawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-710X","authenticated-orcid":false,"given":"Gamal M.","family":"El Maghraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2865_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/DDDT.S101630","volume":"11","author":"A Sharaf","year":"2017","unstructured":"Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther. 2017;11:463\u20137. https:\/\/doi.org\/10.2147\/DDDT.S101630.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"2865_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/luts.12253","volume":"11","author":"JH Shin","year":"2019","unstructured":"Shin JH, Choo MS. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real\u2010life practice. Low Urin Tract Symptoms. 2019;11(3):151\u20137. https:\/\/doi.org\/10.1111\/luts.12253.","journal-title":"Low Urin Tract Symptoms"},{"issue":"2","key":"2865_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.32553\/ijpba.v7i2.118","volume":"7","author":"KA Prajapati","year":"2019","unstructured":"Prajapati KA, Patel DB, Raval AG. Formulation and evaluation of orally disintegrating tablets of mirabegron. Int J Pharm Biol Sci Arch. 2019;7(2):57\u201379. https:\/\/doi.org\/10.32553\/ijpba.v7i2.118.","journal-title":"Int J Pharm Biol Sci Arch"},{"issue":"5","key":"2865_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1021\/mp300582s","volume":"10","author":"S Takusagawa","year":"2013","unstructured":"Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, et al. Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and\/or influx transport systems. Mol Pharm. 2013;10(5):1783\u201394. https:\/\/doi.org\/10.1021\/mp300582s.","journal-title":"Mol Pharm"},{"issue":"9","key":"2865_CR5","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1248\/cpb.c16-00271","volume":"64","author":"Y Kasashima","year":"2016","unstructured":"Kasashima Y, Yoshihara K, Yasuji T, Sako K, Uchida S, Namiki N. Oral sustained release of a hydrophilic drug using the Lauryl Sulfate Salt\/Complex. Chem Pharm Bull. 2016;64(9):1304\u20139. https:\/\/doi.org\/10.1248\/cpb.c16-00271.","journal-title":"Chem Pharm Bull"},{"issue":"1","key":"2865_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1211\/0022357022511","volume":"56","author":"ES Kostewicz","year":"2004","unstructured":"Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004;56(1):43\u201351. https:\/\/doi.org\/10.1211\/0022357022511.","journal-title":"J Pharm Pharmacol"},{"key":"2865_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejpb.2016.09.014","volume":"109","author":"J Rubbens","year":"2016","unstructured":"Rubbens J, Brouwers J, Tack J, Augustijns P. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122\u20139. https:\/\/doi.org\/10.1016\/j.ejpb.2016.09.014.","journal-title":"Eur J Pharm Biopharm"},{"key":"2865_CR8","unstructured":"FDA, Mirabegron. Clinical pharmacology and Biopharmaceutics review(s). FDA-Center for drug evaluat\u0131on and research, USA. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202611Orig1s000ClinPharmR.pdf."},{"issue":"3","key":"2865_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clinthera.2013.02.014","volume":"35","author":"J Lee","year":"2013","unstructured":"Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, et al. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. Clin Ther. 2013;35(3):333\u201341. https:\/\/doi.org\/10.1016\/j.clinthera.2013.02.014.","journal-title":"Clin Ther"},{"key":"2865_CR10","unstructured":"TGA. Extract from the Clinical Evaluation Report for mirabegron. Therapeutic Goods Administration, Australia. 2013. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-mirabegron-140109-cer.pdf."},{"key":"2865_CR11","doi-asserted-by":"publisher","first-page":"105363","DOI":"10.1016\/j.jddst.2024.105363","volume":"92","author":"S Herma","year":"2024","unstructured":"Herma S, Parmar R, Dudhat K, Shah S, Soniwala M, Dudhrejiya A, et al. Preparation and characterization of novel mirabegron salts for sustaining dissolution and improving diffusion\/permeability. J Drug Deliv Sci Technol. 2024;92:105363. https:\/\/doi.org\/10.1016\/j.jddst.2024.105363.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"2865_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756287212457114","volume":"4","author":"E Sacco","year":"2012","unstructured":"Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012;4(6):315\u201324. https:\/\/doi.org\/10.1177\/1756287212457114.","journal-title":"Ther Adv Urol"},{"issue":"8","key":"2865_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED, Mirabegron. A review in overactive bladder syndrome. Drugs. 2018;78(8):833\u201344. https:\/\/doi.org\/10.1007\/s40265-018-0924-4.","journal-title":"Drugs"},{"issue":"6","key":"2865_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2174\/1567201812666150310151238","volume":"12","author":"AM Elwerfalli","year":"2015","unstructured":"Elwerfalli AM, Ghanchi Z, Rashid F, Alany G, ElShaer R. New generation of orally disintegrating tablets for sustained drug release: a propitious outlook. Curr Drug Del. 2015;12(6):652\u201367. https:\/\/doi.org\/10.2174\/1567201812666150310151238.","journal-title":"Curr Drug Del"},{"issue":"3","key":"2865_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/jphp.12516","volume":"68","author":"AA Sultan","year":"2016","unstructured":"Sultan AA, El-Gizawy SA, Osman MA, El Maghraby GM. Colloidal carriers for extended absorption window of furosemide. J Pharm Pharmacol. 2016;68(3):324\u201332. https:\/\/doi.org\/10.1111\/jphp.12516.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"2865_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1021\/mp060042f","volume":"3","author":"JS Kim","year":"2006","unstructured":"Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm. 2006;3(6):686\u201394. https:\/\/doi.org\/10.1021\/mp060042f.","journal-title":"Mol Pharm"},{"key":"2865_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.biopha.2018.07.117","volume":"106","author":"H Yang","year":"2018","unstructured":"Yang H, Zhai B, Fan Y, Wang J, Sun J, Shi Y, Guo D. Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model. Biomed Pharmacother. 2018;106:1563\u20139. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.117.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2865_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/08982104.2017.1343835","volume":"28","author":"AA Sultan","year":"2018","unstructured":"Sultan AA, El-Gizawy SA, Osman MA, El Maghraby GM. Niosomes for oral delivery of nateglinide: in situ-in vivo correlation. J Liposome Res. 2018;28(3):209\u201317. https:\/\/doi.org\/10.1080\/08982104.2017.1343835.","journal-title":"J Liposome Res"},{"issue":"1","key":"2865_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0976-9668.71663","volume":"1","author":"P Dey","year":"2010","unstructured":"Dey P, Maiti S. Orodispersible tablets: a new trend in drug delivery. J Nat Sci Biol Med. 2010;1(1):2. https:\/\/doi.org\/10.4103\/0976-9668.71663.","journal-title":"J Nat Sci Biol Med"},{"issue":"6","key":"2865_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/10837450.2013.813543","volume":"19","author":"GM El Maghraby","year":"2014","unstructured":"El Maghraby GM, Elsergany RN. Fast disintegrating tablets of nisoldipine for intra-oral administration. Pharm Dev Technol. 2014;19(6):641\u201350. https:\/\/doi.org\/10.3109\/10837450.2013.813543.","journal-title":"Pharm Dev Technol"},{"issue":"4","key":"2865_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/clpt.2013.241","volume":"95","author":"S Misaka","year":"2014","unstructured":"Misaka S, Yatabe J, M\u00fcller F, Takano K, Kawabe K, Glaeser H, et al. Green Tea Ingestion greatly reduces plasma concentrations of Nadolol in healthy subjects. Clin Pharmacol Ther. 2014;95(4):432\u20138. https:\/\/doi.org\/10.1038\/clpt.2013.241.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2865_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/pharmaceutics10030149","volume":"10","author":"JH An","year":"2018","unstructured":"An JH, Lim C, Kiyonga AN, Chung IH, Lee IK, Mo K, et al. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. Pharmaceutics. 2018;10(3):149. https:\/\/doi.org\/10.3390\/pharmaceutics10030149.","journal-title":"Pharmaceutics"},{"key":"2865_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10847-019-00955-1","volume":"96","author":"P Mandpe","year":"2020","unstructured":"Mandpe P, Prabhakar B, Shende P. 23 full factorial design for optimization of stable amorphous host\u2013guest-based mirabegron complex for extended-release action. J Incl Phenom Macrocycl Chem. 2020;96:111\u201323. https:\/\/doi.org\/10.1007\/s10847-019-00955-1.","journal-title":"J Incl Phenom Macrocycl Chem"},{"issue":"4","key":"2865_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1017\/S0885715617001129","volume":"32","author":"JHQ Mendoza","year":"2017","unstructured":"Mendoza JHQ, Henao J, Aparicio AP, Bohorquez ARR. X-ray powder diffraction data and characterization of Mirabegron. Powder Diffr. 2017;32(4):290\u20134. https:\/\/doi.org\/10.1017\/S0885715617001129.","journal-title":"Powder Diffr"},{"issue":"3","key":"2865_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ac800987m","volume":"47","author":"A Caillet","year":"2008","unstructured":"Caillet A, Puel F, Fevotte G. Quantitative in situ monitoring of citric acid phase transition in water using Raman spectroscopy. Chem Eng Process. 2008;47(3):377\u201382. https:\/\/doi.org\/10.1021\/ac800987m.","journal-title":"Chem Eng Process"},{"issue":"2","key":"2865_CR26","first-page":"244","volume":"4","author":"R Chadha","year":"2012","unstructured":"Chadha R, Saini A, Arora P, Chanda S, Jain D. Cocrystals of efavirenz with selected coformers: preparation and characterization. Int J Pharm Pharm Sci. 2012;4(2):244\u201350.","journal-title":"Int J Pharm Pharm Sci"},{"issue":"1","key":"2865_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.29228\/JCHAR.54066","volume":"2","author":"JN Oraeluno","year":"2022","unstructured":"Oraeluno JN, Obasi JC, Adelaja E, Bamigbola NEV, Joseph BA. Preparation and Comparative Evaluation of Physicochemical Properties of Microcrystalline Cellulose Derived from Saccharum officinarum L (Poaceae) with Avicel (R) PH102. J Charact. 2022;2(1):60\u20138. https:\/\/doi.org\/10.29228\/JCHAR.54066.","journal-title":"J Charact"},{"issue":"5","key":"2865_CR28","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.3390\/ijms13056454","volume":"13","author":"D Hu","year":"2012","unstructured":"Hu D, Liu L, Chen W, Li S, Zhao Y. A novel preparation method for 5-aminosalicylic acid loaded Eudragit S100 nanoparticles. Int J Mol Sci. 2012;13(5):6454\u201368. https:\/\/doi.org\/10.3390\/ijms13056454.","journal-title":"Int J Mol Sci"},{"key":"2865_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.powtec.2015.05.045","volume":"283","author":"J Jablan","year":"2015","unstructured":"Jablan J, Jug M. Development of eudragit\u00ae s100 based pH-responsive microspheres of zaleplon by spray-drying: tailoring the drug release properties. Powder Technol. 2015;283:334\u201343. https:\/\/doi.org\/10.1016\/j.powtec.2015.05.045.","journal-title":"Powder Technol"},{"issue":"1","key":"2865_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1208\/s12249-015-0426-6","volume":"5","author":"T Parikh","year":"2016","unstructured":"Parikh T, Gupta SS, Meena A, Serajuddin AT. Investigation of thermal and viscoelastic properties of polymers relevant to hot melt extrusion-III: polymethacrylates and polymethacrylic acid based polymers. J Excip Food Chem. 2016;5(1):56\u201364. https:\/\/doi.org\/10.1208\/s12249-015-0426-6.","journal-title":"J Excip Food Chem"},{"key":"2865_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jddst.2017.02.003","volume":"40","author":"S Guo","year":"2017","unstructured":"Guo S, Wang G, Wu T, Bai F, Xu J, Zhang X. Solid dispersion of berberine hydrochloride and Eudragit\u00ae S100: Formulation, physicochemical characterization and cytotoxicity evaluation. J Drug Deliv Sci Technol. 2017;40:21\u20137. https:\/\/doi.org\/10.1016\/j.jddst.2017.02.003.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"2865_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1691\/ph.2007.5.6077","volume":"62","author":"R Raffin","year":"2007","unstructured":"Raffin R, Colom\u00e9 L, Haas S, Jornada D, Pohlmann A, Guterres S. Development of HPMC and eudragit S100\u00ae blended microparticles containing sodium pantoprazole. Pharmazie. 2007;62(5):361\u20134. https:\/\/doi.org\/10.1691\/ph.2007.5.6077.","journal-title":"Pharmazie"},{"issue":"1\u20132","key":"2865_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0378-5173(01)00995-4","volume":"235","author":"V Kumar","year":"2002","unstructured":"Kumar V, de la Luz Reus-Medina M, Yang D. Preparation, characterization, and tabletting properties of a new cellulose-based pharmaceutical aid. Int J Pharm. 2002;235(1\u20132):129\u201340. https:\/\/doi.org\/10.1016\/s0378-5173(01)00995-4.","journal-title":"Int J Pharm"},{"issue":"5","key":"2865_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/10837450.2016.1242625","volume":"23","author":"MF Arafa","year":"2018","unstructured":"Arafa MF, El-Gizawy SA, Osman MA, El Maghraby GM. Xylitol as a potential co-crystal co-former for enhancing dissolution rate of felodipine: preparation and evaluation of sublingual tablets. Pharm Dev Technol. 2018;23(5):454\u201363. https:\/\/doi.org\/10.1080\/10837450.2016.1242625.","journal-title":"Pharm Dev Technol"},{"issue":"8","key":"2865_CR35","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/03639045.2019.1571504","volume":"45","author":"EA Essa","year":"2019","unstructured":"Essa EA, Elbasuony AR, Abdelaziz AE, El Maghraby GM. Co-crystallization for enhanced dissolution rate of bicalutamide: preparation and evaluation of rapidly disintegrating tablets. Drug Dev Ind Pharm. 2019;45(8):1215\u201323. https:\/\/doi.org\/10.1080\/03639045.2019.1571504.","journal-title":"Drug Dev Ind Pharm"},{"issue":"5","key":"2865_CR36","doi-asserted-by":"publisher","first-page":"973","DOI":"10.20959\/wjpps20185-11502","volume":"7","author":"D Patal","year":"2018","unstructured":"Patal D, Patal D. Physicochemical characterization and in vitro dissolution enhancement of Mirabegron using solid dispersion method. World J Pharm Pharm Sci. 2018;7(5):973\u201391. https:\/\/doi.org\/10.20959\/wjpps20185-11502.","journal-title":"World J Pharm Pharm Sci"},{"key":"2865_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF02976347","volume":"18","author":"DM Oh","year":"1995","unstructured":"Oh DM, Curl RL, Yong CS, Amidon GL. Effect of micronization on the extent of drug absorption from suspensions in humans. Arch Pharm Res. 1995;18:427\u201333. https:\/\/doi.org\/10.1007\/BF02976347.","journal-title":"Arch Pharm Res"},{"issue":"4","key":"2865_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsps.2013.05.004","volume":"22","author":"K Vandana","year":"2014","unstructured":"Vandana K, Raju YP, Chowdary VH, Sushma M, Kumar NV. An overview on in situ micronization technique\u2013An emerging novel concept in advanced drug delivery. Saudi Pharm J. 2014;22(4):283\u20139. https:\/\/doi.org\/10.1016\/j.jsps.2013.05.004.","journal-title":"Saudi Pharm J"},{"key":"2865_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijbiomac.2013.05.021","volume":"60","author":"S Mallick","year":"2013","unstructured":"Mallick S, Pradhan SK, Mohapatra R. Effects of microcrystalline cellulose based comilled powder on the compression and dissolution of ibuprofen. Int J Biol Macromol. 2013;60:148\u201355. https:\/\/doi.org\/10.1016\/j.ijbiomac.2013.05.021.","journal-title":"Int J Biol Macromol"},{"key":"2865_CR40","doi-asserted-by":"publisher","first-page":"121033","DOI":"10.1016\/j.ijpharm.2021.121033","volume":"608","author":"N Pe\u0161i\u0107","year":"2021","unstructured":"Pe\u0161i\u0107 N, Dap\u010devi\u0107 A, Ivkovi\u0107 B, Kachrimanis K, Mitri\u0107 M, Ibri\u0107 S, Medarevi\u0107 D. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol. Int J Pharm. 2021;608:121033. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121033.","journal-title":"Int J Pharm"},{"issue":"7","key":"2865_CR41","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.xphs.2020.04.008","volume":"109","author":"M Ruponen","year":"2020","unstructured":"Ruponen M, Rusanen H, Laitinen R. Dissolution and permeability properties of co-amorphous formulations of hydrochlorothiazide. J Pharm Sci. 2020;109(7):2252\u201361. https:\/\/doi.org\/10.1016\/j.xphs.2020.04.008.","journal-title":"J Pharm Sci"},{"issue":"1","key":"2865_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.31351\/vol30iss1pp122-132","volume":"30","author":"LS Hussein","year":"2021","unstructured":"Hussein LS, Al-Khedairy EB. Solubility and dissolution enhancement of ebastine by surface solid dispersion technique. Iraqi J Pharm Sci. 2021;30(1):122\u201332. https:\/\/doi.org\/10.31351\/vol30iss1pp122-132.","journal-title":"Iraqi J Pharm Sci"},{"issue":"1\u20133","key":"2865_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.powtec.2010.10.009","volume":"207","author":"FA Maulvi","year":"2011","unstructured":"Maulvi FA, Dalwadi SJ, Thakkar VT, Soni TG, Gohel MC, Gandhi TR. Improvement of dissolution rate of aceclofenac by solid dispersion technique. Powder Technol. 2011;207(1\u20133):47\u201354. https:\/\/doi.org\/10.1016\/j.powtec.2010.10.009.","journal-title":"Powder Technol"},{"issue":"1","key":"2865_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/10837459809009868","volume":"9","author":"W Putranti","year":"2019","unstructured":"Putranti W, Widiyastuti L, Ulfani F. Enhancing the dissolution rate of mefenamic acid with solid dispersion system using avicel PH-101. Pharmaciana. 2019;9(1):119\u201328. https:\/\/doi.org\/10.3109\/10837459809009868.","journal-title":"Pharmaciana"},{"issue":"10","key":"2865_CR45","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1691\/ph.2008.7416","volume":"63","author":"L Asghar","year":"2008","unstructured":"Asghar L, Chandran S. Design and evaluation of pH modulated controlled release matrix systems for colon specific delivery of indomethacin. Pharmazie. 2008;63(10):736\u201342. https:\/\/doi.org\/10.1691\/ph.2008.7416.","journal-title":"Pharmazie"},{"issue":"2","key":"2865_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/03639049609041983","volume":"22","author":"MA Khan","year":"1996","unstructured":"Khan MA, Dib J, Reddy LK. Statistical optimization of ketoprofen-Eudragit\u00ae S100 coprecipitates to obtain controlled-release tablets. Drug Dev Ind Pharm. 1996;22(2):135\u201341. https:\/\/doi.org\/10.3109\/03639049609041983.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2865_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2478\/acph-2014-0002","volume":"64","author":"GM El Maghraby","year":"2014","unstructured":"El Maghraby GM, Elzayat EM, Alanazi FK. Investigation of in situ gelling alginate formulations as a sustained release vehicle for co-precipitates of dextromethrophan and Eudragit S 100. Acta Pharm. 2014;64(1):29\u201344. https:\/\/doi.org\/10.2478\/acph-2014-0002.","journal-title":"Acta Pharm"},{"issue":"3","key":"2865_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/03639049609058569","volume":"22","author":"K Goracinova","year":"1996","unstructured":"Goracinova K, Klisarova L, Simov A, Fredro-Kumbaradzi E, Petrusevska-Tozi L. Preparation, physical characterization, mechanisms of drug\/polymer interactions, and stability studies of controlled-release solid dispersion granules containing weak base as active substance. Drug Dev Ind Pharm. 1996;22(3):255\u201362. https:\/\/doi.org\/10.3109\/03639049609058569.","journal-title":"Drug Dev Ind Pharm"},{"key":"2865_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-020-01914-7","volume":"22","author":"M Monschke","year":"2021","unstructured":"Monschke M, Kayser K, Wagner KG. Influence of particle size and drug load on amorphous solid dispersions containing pH-dependent soluble polymers and the weak base ketoconazole. AAPS PharmSciTech. 2021;22:1\u201311. https:\/\/doi.org\/10.1208\/s12249-020-01914-7.","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"2865_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijpharm.2013.07.072","volume":"455","author":"JI Kim","year":"2013","unstructured":"Kim JI, Cho SM, Cui JH, Cao QR, Oh E, Lee BJ. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex. Int J Pharm. 2013;455(1\u20132):31\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.07.072.","journal-title":"Int J Pharm"},{"key":"2865_CR51","doi-asserted-by":"publisher","first-page":"370938","DOI":"10.1155\/2013\/370938","volume":"2013","author":"BK Patel","year":"2013","unstructured":"Patel BK, Parikh RH, Aboti PS. Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment. J Drug Deliv. 2013;2013:370938. https:\/\/doi.org\/10.1155\/2013\/370938.","journal-title":"J Drug Deliv"},{"issue":"3","key":"2865_CR52","first-page":"1281","volume":"8","author":"GA Shazly","year":"2013","unstructured":"Shazly GA, Tawfeek HM, Ibrahim MA, Auda SH, El-Mahdy M. Formulation and evaluation of fast dissolving tablets containing taste-masked microspheres of diclofenac sodium for sustained release. Dig J Nanomater Bios. 2013;8(3):1281\u201393.","journal-title":"Dig J Nanomater Bios"},{"issue":"3","key":"2865_CR53","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ejpb.2007.09.010","volume":"68","author":"M Abbaspour","year":"2008","unstructured":"Abbaspour M, Sadeghi F, Garekani HA. Design and study of ibuprofen disintegrating sustained-release tablets comprising coated pellets. Eur J Pharm Biopharm. 2008;68(3):747\u201359. https:\/\/doi.org\/10.1016\/j.ejpb.2007.09.010.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"2865_CR54","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3109\/03639045.2012.664146","volume":"39","author":"Q Wei","year":"2013","unstructured":"Wei Q, Yang F, Luan L. Preparation and in vitro\/in vivo evaluation of a ketoprofen orally disintegrating\/sustained release tablet. Drug Dev Ind Pharm. 2013;39(6):928\u201334. https:\/\/doi.org\/10.3109\/03639045.2012.664146.","journal-title":"Drug Dev Ind Pharm"},{"key":"2865_CR55","doi-asserted-by":"publisher","unstructured":"Shamma RN, Basalious EB, Shoukri RA. Development and optimization of a multiple-unit controlled release formulation of a freely water soluble drug for once-daily administration. Int J Pharm. 2011;405(1\u20132):102\u2009\u2013\u200912. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.12.003.","DOI":"10.1016\/j.ijpharm.2010.12.003"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02865-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-02865-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02865-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:38:14Z","timestamp":1725395894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-02865-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2865"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-02865-z","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"13 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are neither financial nor non-financial conflicts of interest among the contributing authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"167"}}